Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1756-6614
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer ; volume:16 ; number:1 ; day:1 ; month:3 ; year:2023 ; pages:1-11 ; date:12.2023
Thyroid research ; 16, Heft 1 (1.3.2023), 1-11, 12.2023

Urheber
Lang, Matthias
Longerich, Thomas
Anamaterou, Chrysanthi
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s13044-023-00147-7
URN
urn:nbn:de:101:1-2023041221072499716621
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:54 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Lang, Matthias
  • Longerich, Thomas
  • Anamaterou, Chrysanthi
  • SpringerLink (Online service)

Ähnliche Objekte (12)

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAF V600E/Mt to Vemurafenib

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Metastatic BRAF V600E-Mutated Thyroid Carcinoma: Molecular/Genetic Profiling Brings a New Therapeutic Option

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

BRAF V600E -mutated serrated colorectal neoplasia drives transcriptional activation of cholesterol metabolism

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

BRAF activating mutations involving the β3-αC loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report

Verbundene Objekte